Thymic-derived CD4+25+FoxP3+ regulatory T cells (Tregs) are required to suppress autoimmunity and limit foreign antigen responses. Our first-in-human phase I dose escalation trial of ex vivo expanded human Tregs proved efficacious in significantly reducing the incidence of acute graft-vs-host disease (GVHD). Two major limitations to uniform efficacy were identified: Problem 1 (achieving optimal suppression): The %suppression was variable. Problem 2 (maintaining adequate Treg:Teffector ratios): Ratios of 1:5.5 achieved were well below the desired ratios of e1:1 need for GVHD prevention in mice; no Tregs were detected by 2 weeks post-transfer.
Aim 1 will focus on Problem 1. PKC-q coordinates immune function, which results in its movement to the immunological synapse (direct contact point between T cell and antigen-presenting cell) in Teffectors but not Tregs. PKC-q deficient murine Teffectors are unable to cause GVHD but can retain anti-tumor and anti- pathogen responses. Tregs treated with a small molecule PKC-q inhibitor had augmented suppressor function and were more effective in suppressing murine colitis.
In aim 1, focused on Problem 1, we will use small molecule PKC-q inhibitors in vitro or in vivo to test the hypotheses that murine and human Treg potency for GVHD suppression is limited by movement of PKC-q into the immunological synapse.
In aim 2, focused on Problem 2, we will test the hypothesis that sustained IL-2R signaling pathways will provide a PKC- q independent route to Treg expansion and GVHD suppression. We will use 3 strategies to improve Treg mediated GVHD suppression: (a) administer IL-2/anti-IL2 antibody complexes or low dose IL-2 to preferentially expand murine and human Tregs vs Teffectors; (b) Constitutively express STAT5b in murine and human Tregs based upon our findings that constitutive STAT5b promotes murine Treg generation, proliferation and function including GVHD suppression, bypassing the need for IL-2, present in limiting amounts in vivo; and (c) increase b-catenin signaling using a GSK-3b inhibitor in vitro or expressing a stabilized b-catenin in human Tregs since stabilized b-catenin reduces Treg dependency upon IL-2 and provides a marked enhancement of murine Treg survival and efficacy in preventing colitis.
In aim 3, we will select the best 1-2 approaches, derived from studies in aims 1 and 2, for testing in preclinical GVHD models for the preservation of beneficial immune responses later post-transplant. Long-term chimeras that do not succumb to GVHD lethality, as a result of preferred approaches developed aims 1 and 2, will be challenged with leukemia cells or bacterial or viral pathogens to quantify the extent to which the immune system can respond to life-threatening complications post-transplant.

Public Health Relevance

Our team of experts will develop novel approaches and gain biological insights into Tregs. Our findings will have broad implications for the use of Tregs in controlling adverse immune responses by focusing on translational applications to harness the full power of Tregs for hematopoietic stem cell and solid transplantation as well as autoimmunity settings.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL118979-02
Application #
8837683
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Di Fronzo, Nancy L
Project Start
2014-04-15
Project End
2018-02-28
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
2
Fiscal Year
2015
Total Cost
$423,548
Indirect Cost
$128,049
Name
University of Minnesota Twin Cities
Department
Pediatrics
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Zitzer, Nina C; Snyder, Katiri; Meng, Xiamoei et al. (2018) MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. J Immunol 200:4170-4179
Habtetsion, Tsadik; Ding, Zhi-Chun; Pi, Wenhu et al. (2018) Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-?-Dependent Intensification of Oxidative Stress and Tumor Cell Death. Cell Metab 28:228-242.e6
Hippen, K L; O'Connor, R S; Lemire, A M et al. (2017) In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. Am J Transplant 17:3098-3113
Purroy, Carolina; Fairchild, Robert L; Tanaka, Toshiaki et al. (2017) Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol 28:2377-2392
McKenna Jr, David H; Sumstad, Darin; Kadidlo, Diane M et al. (2017) Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy 19:250-262
Fuchs, Anke; Gliwi?ski, Mateusz; Grageda, Nathali et al. (2017) Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Front Immunol 8:1844
Kean, Leslie S; Turka, Laurence A; Blazar, Bruce R (2017) Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev 276:192-212
Zanin-Zhorov, Alexandra; Kumari, Sudha; Hippen, Keli L et al. (2017) Human in vitro-induced regulatory T cells display Dlgh1dependent and PKC-? restrained suppressive activity. Sci Rep 7:4258

Showing the most recent 10 out of 55 publications